表紙
市場調查報告書
商品編碼
961510

肌切開術的全球市場:2020-2027

Global Myomectomy Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 190 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球子宮肌切開術市場的增長主要由子宮肌瘤的流行率上升以及對子宮疾病的診斷和治療的需求不斷增長所驅動。

子宮肌瘤是女性中最常見的骨盆腫瘤,全球患病率為21.4%。到50歲時,約有20%至80%的婦女會患子宮肌瘤。子宮肌瘤在40多歲和50多歲的女性中很常見。到80歲時,約80%的非洲裔美國婦女會患子宮肌瘤。隨著老年人更易患婦科問題,例如荷爾蒙失調,子宮異常出血和月經週期不規律,全球肌瘤摘除術市場對老年婦女的需求不斷增長。正在刺激和推動市場增長。

本報告調查了全球子宮肌切開術市場,並提供系統信息,例如市場概況,按細分市場和地區劃分的市場規模預測,主要公司的概況以及競爭情況分析。

目錄

第1章全球子宮肌切開術市場:調查方法/範圍

  • 調查方法
  • 調查目的/範圍

第2章全球子宮肌切開術市場:市場定義/概述

第3章全球子宮肌切開術市場:執行摘要

  • 市場細分:按類型
  • 市場細分:按產品
  • 市場細分:按最終用戶
  • 市場細分:按地區

第4章全球子宮肌切開術市場:市場動態

  • 市場影響因素
    • 促進因素
    • 抑製器
  • 影響分析
  • 市場機會

第5章全球子宮肌切開術市場:行業因素

  • 波特的五力分析
  • 流行病學
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 未滿足的需求
  • COVID-19的影響分析

第6章全球子宮肌切開術市場:按類型

  • 簡介
  • 市場規模分析/同比增長率分析:按類型
  • 市場吸引力指數:按類型
    • 腹腔鏡
    • 腹部
    • 子宮鏡
    • 機器人

第7章全球子宮肌切開術市場:按產品

  • 簡介
  • 市場規模分析/同比增長率分析:按產品
  • 市場吸引力指數:按產品
    • 腹腔鏡電粉碎機
    • 腹腔鏡封口機
    • 諧波手術刀
    • 其他

第8章全球子宮肌切開術市場:按最終用戶

  • 簡介
  • 市場規模分析/同比增長率分析:按最終用戶劃分
  • 市場吸引力指數:按最終用戶劃分
    • 醫院與診所
    • 手術中心
    • 其他

第9章肌切開術市場:按地區

  • 簡介
  • 市場規模分析/同比增長率分析:按地區
  • 市場吸引力指數:按地區
  • 北美
    • 簡介
    • 特定地區的主要動態
    • 市場規模分析/同比增長率分析:按類型
    • 市場規模分析/同比增長率分析:按產品
    • 市場規模分析/同比增長率分析:按最終用戶劃分
    • 市場規模分析/同比增長率分析:按國家
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第10章競爭情況

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析

第11章公司簡介

  • 波士頓科學公司
    • 公司簡介
    • 投資組合/說明
    • 主要亮點
    • 財務概覽
  • Halt Medical, Inc.
  • CooperSurgical Inc.
  • F. Hoffmann-La Roche Ltd
  • KARL STORZ SE & Co. KG
  • Richard Wolf Medical Instruments
  • Siemens
  • Eli Lilly and Company
  • AbbVie Inc.
  • Johnson & Johnson Services

第12章全球子宮肌切開術市場:重要考慮因素

第13章全球子宮肌切開術市場-DataM

  • 附錄
  • 關於我們的公司和服務
  • 聯繫我們
目錄
Product Code: DMOT2667

Market Overview

The Global Myomectomy Market is expected to grow at a high CAGR of 9.1% during the forecasting period (2022-2029).

Myomectomy is a surgical procedure to remove uterine fibroids. These common non-cancerous growths in the uterus of women at their childbearing age, cause symptoms such as heavy bleeding during the menstrual cycle, increased menstrual cramping, pain in the pelvis or lower back, and swelling enlargement of the abdomen. Myomectomy preserves the chances of women getting pregnant.

Market Dynamics

The global myomectomy market growth is driven by the rising prevalence of uterine fibroids and the growing demand for the diagnosis and treatment of uterine disorders. The increasing number of patients suffering from uterine fibroids and associated conditions, the growing number of less invasive procedures, and the rising adoption of technologically advanced devices for safe and effective myomectomy procedures are the major factors expected to drive the market.

The growing demand for diagnosis and treatment of uterine disorder will drive the market growth

Uterine fibroids are the most common pelvic tumors in women, occurring globally with a prevalence of 21.4%. About 20% to 80% of women develop fibroids by the time they reach age 50. Fibroids are common in women in their 40s and early 50s. About 80% of African American women will develop fibroids by the age of 50. The increasing female aging population is propelling the growth of the market as the elderly population is more susceptible to gynecological problems, such as hormonal imbalance, abnormal uterine bleeding, and irregular menstrual cycle, which is fueling the demand for the global myomectomy market. Another research study published in 2017, which included approximately 5,000 Italian women with uterine fibroids, showed that 95% of the surgeries performed included women in the age group of 36-55 years. Additionally, a rise in the number of minimally invasive surgical procedures due to fewer complications and reduced hospital stay is anticipated to drive the growth of the market. Technological advancements, such as the rise in the number of robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment, may also contribute to the growth of the myomectomy market.

The launch of technologically advanced products due to the increasing number of myomectomy procedures for uterine fibroids is likely to boost the market growth. Technological advancements such as the introduction of laparoscopic or robotically assisted myomectomy procedures have shown incisionless surgery with no or minimal side effects for fibroids treatment. As compared to the open abdominal myomectomy surgery, with robotic myomectomy patient experience less blood loss with fewer complication rates, have a shorter hospital stay, and returns to normal activities more quickly. Thus, the use of robots for myomectomy surgery and their several advantages over conventional laparoscopy (open surgery), have been widely accepted and incorporated into the field of reproductive surgery.

The complications associated with myomectomy will hamper the growth of the market

However, myomectomy is associated with hemorrhage, infection, bowel obstruction, adhesion formation, damage to the bowel, bladder, fallopian tube, ureter, wound infection, and wound separation. About 20-25% of patients undergoing myomectomy require another pelvic operation, usually hysterectomy because of recurrence of symptoms. Recurrent myomas are common, especially in patients with multiple myomas. Patients with a solitary myoma have a 27% recurrence rate, and those with multiple myomas have a rate of 59%. Patients undergoing myomectomy should be counseled pre-operatively about these risks and must understand that myomectomy may not be possible.

COVID-19 Impact Analysis

The impact of the COVID-19 pandemic is significant on the myomectomy market. With the surge of COVID-19 cases across the world, healthcare services diverted their resources toward the patients suffering from COVID-19. Guidelines and recommendations were provided for the management of patients during the pandemic. This resulted in hospitals prioritizing emergency procedures and delaying or postponing elective procedures, such as myomectomy surgery, leading to a backlog of patients waiting for their surgeries for months. A CovidSurg Collaborative study, 2020, estimated that around 28 million operations would be delayed during the peak 12-week disruption due to COVID-19, including 81.7% benign surgeries. With conditions returning to normal, myomectomy procedures are expected to recover gradually.

Segment Analysis

The abdominal segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The abdominal segment, also known as the open type, is considered the classic myomectomy surgery. This procedure is performed by making a small horizontal incision (or a vertical incision for a larger uterus) across the abdomen region of the body. With the rise in the number of patients with uterine fibroids, the demand for myomectomy procedures may also increase. Abdominal myomectomy is the highly performed and preferred type of treatment. A 2017 UK research study published on Gynecological Surgery, Springer Open, involving physician consultants, identifies that nearly 70% of them perform open myomectomy. The open type is preferred based on the size and location of fibroids. Hence, due to such activities across different countries, the number of procedures is expected to grow further over the forecast period.

Geographical Analysis

North America region holds the largest market share of the global myomectomy market

North America dominates the market for myomectomy and is expected to show a similar trend over the forecast period, owing to the rising prevalence of uterine fibroid. A 2018 article published in the American Journal of Obstetrics and Gynecology shows that the prevalence of uterine fibroids was found to be 10% in the United States, with higher occurring rates observed for black women and other ethnic or racial groups. Additionally, according to the World Economic Outlook 2021 by IMF, real GDP is projected to grow by 6.4% in the United States and 5% in Canada. These factors, coupled with high reimbursement rates and government initiatives, contribute to North America occupying the largest share of the overall myomectomy market.

The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at the age of 35, which increased to more than 80% by the age of 50 years among women.

Also, the adoption of minimally invasive and effective alternatives to open surgeries and technological advancements in devices with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the growth of the myomectomy market in this region.

Competitive Landscape

The myomectomy market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., Intuitive Surgical Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the Myomectomy Market globally. For instance, in August 2020, Hologic Inc. announced the acquisition of Acessa Health Inc., a privately held company focused on minimally invasive therapies for fibroids. This acquisition is anticipated to strengthen Hologic's fibroid treatment product portfolio.

Medtronic plc

Overview:

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical-Surgical Portfolio, and Diabetes Operating Unit.

Product Portfolio:

Veriset Hemostatic Patch: The Veriset patch is designed to address the unmet need for a simple to use, fast, and highly effective hemostatic patch. Medtronic launched the Veriset patch. It is designed to help to achieve hemostasis quickly and consistently, in ~1 minute.

Why Purchase the Report?

Visualize the composition of the global myomectomy market segmentation by type, product, end-user, and region highlighting the key commercial assets and players.

Identify commercial opportunities in the global myomectomy market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of global myomectomy market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global myomectomy market report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 190 pages.

Table of Contents

1. Global Myomectomy Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Myomectomy Market -Market Definition and Overview

3. Global Myomectomy Market - Executive Summary

  • 3.1. Market Snippet By Type
  • 3.2. Market snippet By Product
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Myomectomy Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The growing demand for diagnosis and treatment of the uterine disorder
      • 4.1.1.2. Rise in Minimally Invasive Procedures
    • 4.1.2. Restraints:
      • 4.1.2.1. The complications associated with myomectomy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Myomectomy Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Myomectomy Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Product
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. Global Myomectomy Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Laparoscopic*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Abdominal
  • 7.4. Hysteroscopic
  • 7.5. Robotic

8. Global Myomectomy Market - By Product

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 8.1.2. Market Attractiveness Index, By Product
  • 8.2. Laparoscopic Power Morcellators*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Laparoscopic Sealer
  • 8.4. Harmonic Scalpel
  • 8.5. Others

9. Global Myomectomy Market - By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals & Clinics *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Surgical Centers
  • 9.4. Other

10. Global Myomectomy Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Myomectomy Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Myomectomy Market - Company Profiles

  • 12.1. Medtronic PLC*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Stryker Corporation
  • 12.3. ConMed Corporation
  • 12.4. INSIGHTEC Ltd
  • 12.5. CooperSurgical Inc.
  • 12.6. Hologic Inc.
  • 12.7. Intuitive Surgical Inc.
  • 12.8. KARL STORZ SE & Co. KG
  • 12.9. B Braun
  • 12.10. Richard Wolf Medical Instruments

LIST NOT EXHAUSTIVE

13. Global Myomectomy Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us